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Abstract
Naegleria fowleri is a thermophilic free-living ameba that causes primary amebic 
meningoencephalitis. Infections are nearly always fatal. We present the third well-documented 
survivor of this infection in North America. Survival most likely resulted from a combination of 
early identification and treatment, use of a combination of antimicrobials including miltefosine 
and management of elevated intracranial pressure based on traumatic brain injury principles.
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Naegleria fowleri is a thermophilic free-living ameba found in warm freshwater. Infection is 
rare and occurs when water containing the ameba enters the nose and subsequently invades 
the brain. Infection with N. fowleri causes primary amebic meningoencephalitis (PAM), 
resulting in destruction of brain tissue and cerebral edema. There have been two well-
documented survivors in North America: one in California in 19781–2 and one in Mexico in 
2003.3 We present the third documented survivor of PAM in North America.
Case
The patient, a previously healthy 12-year-old female, presented to the emergency 
department with a two-day history of headache and a one-day history of fever (39.4°C), 
along with nausea, vomiting and somnolence. She had a normal neurologic exam. She 
reported swimming at an outdoor water park seven days prior to symptom onset. Initial 
laboratory evaluation included peripheral white blood cell count of 18.4 cells/μL (77% 
segmented, 13% banded neutrophils). Cerebrospinal fluid (CSF) revealed a white blood cell 
count of 3675 cells/μL (86% segmented neutrophils), red blood cell count of 53 cells/μL, 
protein of 374 mg/dL and glucose of 22 mg/dL. The Giemsa-Wright stain of the CSF 
revealed amebae consistent with N. fowleri. The initial computed tomography scan of her 
brain was normal.
She was admitted to the pediatric intensive care unit on July 19, 2013 and started on the 
following: conventional amphotericin B 1.5mg/kg/day intravenously in two divided doses, 
fluconazole 10mg/kg/day, rifampin 10mg/kg/day and azithromycin 10mg/kg/day.1, 3 
Dexamethasone was initiated concurrently. After three days, the amphotericin B was 
decreased to 1mg/kg/day.1 Approximately 36 hours after admission, she was started on 
miltefosine 50mg every eight hours. Consent was obtained from the family prior to 
administering miltefosine.
Almost 24 hours after admission, she developed a right-sided abducens nerve palsy. An 
extraventricular drain (EVD) was placed in the operating room, and initial intracranial 
pressure (ICP) was approximately 50 mmHg. Intrathecal amphotericin B was started at a 
dose of 1.5mg daily for two days followed by a dose of 1mg every other day for eight days.1 
On the third day of hospitalization, she developed worsening intracranial pressure. 
Management of her cerebral edema (goal ICP below 20 mmHg) included: drainage of CSF, 
hyperosmolar therapy with mannitol and 3% saline, moderate hyperventilation (goal pCO2 
of 30–35 mmHg), and induced hypothermia (32–34°C). Cerebral edema resolved after 
approximately two weeks. (Figure 1)
Her initial CSF specimen grew N. fowleri on culture and was positive for N. fowleri by 
polymerase chain reaction (PCR). By day three, her CSF specimen was culture negative for 
N. fowleri. Serial CSF specimens showed decreasing white blood cells and decreasing 
amounts of N. fowleri DNA on PCR.
A magnetic resonance image (MRI) of her brain two weeks into her illness revealed blood in 
the frontal lobes and multiple areas of restricted diffusion primarily in the cerebellum, right 
internal capsule and corpus collosum (Figure 2). A repeat MRI of her brain one week later 
showed improvement. She completed 26 days of a planned 28-day course of antimicrobials 
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(miltefosine, azithromycin, rifampin and fluconazole), which were stopped early due to 
nausea and vomiting. Upon transfer to the rehabilitation unit, the patient had left-sided 
weakness, dysarthria and dysphagia. After 55 days of hospitalization, she was discharged 
home. At six months post infection, her level of functioning was normal and without 
residual deficits.
Discussion
We report the third documented survivor of N. fowleri PAM in North America. Her survival 
is likely the result of a combination of factors: early diagnosis and treatment, use of a 
combination of antimicrobials including miltefosine4 and management of elevated ICP 
based on traumatic brain injury principles. This is the first report of a patient with PAM 
successfully treated with a regimen that included miltefosine. This is also the first report to 
document successful use of induced hypothermia (32–34°C) in the management of PAM.
Between 1962 and 2013, 132 cases of N. fowleri PAM were reported to the Centers for 
Disease Control and Prevention (CDC).5–6 The number of infections reported each year (0–
8 infections) remains stable.5–6 The majority of these infections occurred in southern-tier 
states. Roughly 75% of infections are associated with swimming in warm freshwater lakes 
and rivers.5–6 The median age of infection is 11 years (range 8 months to 66 years).5–6 
Recently the epidemiology of N. fowleri PAM has changed. Since 2010, two cases were 
reported in Minnesota6–7 as well as single cases identified in Indiana and Kansas.6 This 
suggests that the geographic range of this thermophilic organism may be expanding. In 
addition, infections have been reported in patients exposed to nonsterile tap water that was 
used for sinus irrigation8 or ritual ablution.9
The time from exposure to N. fowleri to the onset of symptoms is approximately 5 days 
(range 1 to 7 days).5 The initial symptoms of PAM are indistinguishable from bacterial 
meningitis. Patients experience rapid deterioration with death resulting from brain injury and 
edema occurring within about 5 days (range 1 to 12 days).5 In the two weeks prior to 
symptom onset, our patient swam in a number of locations. Epidemiologic investigation by 
the state health department suggested that a local water park was the likely source of 
infection. Water samples from only this site tested positive for N. fowleri. Our patient 
developed symptoms seven days after this exposure. She presented to the hospital 
approximately 30 hours after initial symptoms and was started on recommended therapy 
within 36 hours of symptom onset. By comparison, the median time from symptom onset to 
hospital presentation for patients with PAM is two days, and the median time from symptom 
onset to initiation of recommended therapy is three days (CDC unpublished data). Because 
N. fowleri PAM is rare and not often considered as a diagnosis, pre-mortem identification of 
the ameba is often delayed or not attempted, precluding the timely initiation of 
recommended therapy. Early identification and initiation of recommended therapy seems 
critical for survival; however, this timeframe is likely impacted by multiple factors including 
strain virulence, inoculum and host immune response.
The only documented survivor in the United States received amphotericin and miconazole 
intravenously and intrathecally and intravenous rifampin.1–2 The survivor from Mexico 
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received intravenous amphotericin, fluconazole and rifampin.3 Conventional amphotericin 
has a lower minimum inhibitory concentration compared to the liposomal formulation and is 
thus preferred even though the liposomal form has better CSF penetration.10 Other 
medications such as fluconazole, voriconazole and azithromycin have shown activity against 
N. fowleri.10–12 Studies suggest that azithromycin may have a synergistic effect when used 
in combination with amphotericin.13 Recently, miltefosine, an antiparasitic agent, has shown 
in vitro effectiveness against N. fowleri and other clinically important free-living amebae.11 
Although in recent years miltefosine has been used to successfully treat patients with other 
free-living amebae infections14–15, our patient is the first to be successfully treated with 
miltefosine for PAM. Miltefosine is available directly from CDC for treatment of infections 
caused by free-living amebae in the United States.4
Current neuroprotective management principles following brain injury are based on 
maintaining adequate cerebral perfusion, tempering oxygen consumption, and limiting 
intracranial pressure.16 Data suggests that mild-moderate hypothermia (32–34°C) may have 
neuroprotective effects including: lowering ICP, reducing production of reactive oxygen and 
nitrogen species, reduction of proinflammatory cytokine levels, and preventing neuronal 
apoptosis.16–18 Clinical studies evaluating the effects of mild-moderate hypothermia in 
patients with traumatic brain injury and bacterial meningitis have shown conflicting 
results.19–22
N. fowleri initially causes direct damage to surrounding neuronal and other cells through 
direct cell-to-cell interaction as well as release of a number of cytotoxic proteins.2 In 
addition, cytotoxic proteins released by N. fowleri and debris from lysed neuronal and other 
cells generate a cascade of proinflammatory cytokines resulting in hyperinflammation and 
further injury.23 It is possible that the beneficial effects of hypothermia seen in patients with 
traumatic brain injury and bacterial meningitis may also attenuate the inflammatory response 
that occurs in patients with N. fowleri PAM. Cytokine levels were not measured in our 
patient, so it is unclear whether the use of hypothermia impacted the host inflammatory 
response. Although N. fowleri is a thermophilic organism, it is unclear whether the degree of 
hypothermia used in our patient resulted in reduced pathogenicity of the ameba.
The changing epidemiology of N. fowleri necessitates its inclusion in the differential of 
patients with meningoencephalitis, particularly those who report a recent history of 
swimming in warm freshwater, regardless of geographic location, or use of nonsterile water 
for nasal irrigation or ritual ablution. Since early diagnosis and therapy are critical, 
laboratory technicians must be able to quickly identify amebae on CSF specimens. Prompt 
initiation of a regimen including conventional amphotericin, fluconazole, azithromycin and 
rifampin is recommended (Table 1). Miltefosine should be added to this regimen as soon as 
possible. In the presence of signs of increased ICP, we recommend placement of an EVD 
and administration of intrathecal amphotericin (Table 1). Elevated ICP should be 
aggressively managed, maintaining an ICP below 20 mmHg. Administer dexamethasone 
concurrently with the antimicrobials as it was utilized in all three documented survivors, and 
has shown benefit in central nervous system insults due to infectious etiologies.1–3, 24 
Consider also lowering the patient’s core body temperature (32–34°C) as this may have 
beneficial effects beyond lowering ICP. Additional data are needed to determine adequate 
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length of therapy and to determine the effects of hypothermia in the management of PAM. 
Ongoing surveillance and continued reporting of PAM cases are needed to continue to learn 








PCR Polymerase chain reaction
MRI Magnetic resonance image
CDC Centers for Disease Control and Prevention
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Figure 1. The Relationship Between Mean Arterial Pressure, Cerebral Perfusion Pressure, 
Intracranial Pressure and Core Body Temperature During the Management of a Twelve-Year-
Old Female with Naegleria fowleri Primary Amebic Meningoencephalitis
MAP is mean arterial pressure. ICP is intracranial pressure. CPP is cerebral perfusion 
pressure. Temp is temperature. The graph above illustrates our management strategy of 
maintaining CPP above 60mmHg and ICP below 20mmHg. With induction of hypothermia 
(7/22 22:00), ICPs were sustained under 20mmHg. Please note early attempts to rewarm the 
patient on 7/24 and 7/26 led to elevations of ICP. After 5 days of cooling, rewarming the 
patient was met with minimal ICP elevations.
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Figure 2. Noncontrast Axial Magnetic Resonance Images of the Brain of a Patient with Naegleria 
fowleri Primary Amebic Meningoencephalitis
Figure 2a: The axial fluid attenuated inversion recovery (FLAIR) image shows focal edema 
in the left frontal lobe (arrow). Figure 2b: Axial susceptibility-weighted image shows 
hemorrhage within the left frontal edematous lesion (arrow). Figure 2c: Axial FLAIR image 
demonstrates multiple areas of edema in the cerebellum bilaterally (arrows). Figure 2d: 
Axial diffusion-weighted image shows areas of restricted diffusion consistent with acute 
cerebellitis (arrows).
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